X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This collaboration is expected to facilitate the further development of THX-160 for the treatment of pain, following efficacy pre-clinical studies that demonstrated the analgesic advantages of THX-160 over control.
Lead Product(s): THX-160
Therapeutic Area: Neurology Product Name: THX-160
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: The University of Calgary
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 02, 2020
Details:
As part of the joint venture, Therapix transferred to Evero its THX-110 sleep technology, to be fully owned by Evero, under the terms and conditions of an asset purchase agreement.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Evero
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
